Aunque la designación de COVID-19 como emergencia nacional y de...Leer más
Worldwide access to Paxlovid remains inequitable
In a Think Global Health article, IHME staff examine the barriers to acquiring the antiviral Paxlovid, which can greatly reduce the chance of COVID-19 hospitalizations and deaths.
Low- and middle-income nations must contend with licensing dilemmas, lack of supplies, and high costs to gain access to Paxlovid.
“This would be similar to the vaccine situation when rich countries started giving three or four doses while other countries had no vaccines,” said professor Ali Mokdad.
- IHME estimates that 82% of people who died from COVID-19 did not live in high-income countries. The authors call on high-income countries to swiftly make Paxlovid available to people everywhere before a new, more severe variant arises.
Créditos: Comité científico Covid